liver disease in cystic fibrosis: an update

Authors

giuseppe fabio parisi department of medical and pediatric science, bronchopneumology and cystic fibrosis unit, university of catania, catania, italy

giovanna di dio department of medical and pediatric science, bronchopneumology and cystic fibrosis unit, university of catania, catania, italy

chiara franzonello department of medical and pediatric science, bronchopneumology and cystic fibrosis unit, university of catania, catania, italy

alessia gennaro department of medical and pediatric science, bronchopneumology and cystic fibrosis unit, university of catania, catania, italy

abstract

context cystic fibrosis (cf) is the most widespread autosomal recessive genetic disorder that limits life expectation amongst the caucasian population. as the median survival has increased related to early multidisciplinary intervention, other manifestations of cf have emergedespecially for the broad spectrum of hepatobiliary involvement. the present study reviews the existing literature on liver disease in cystic fibrosis and describes the key issues for an adequate clinical evaluation and management of patients, with a focus on the pathogenetic, clinical and diagnostic-therapeutic aspects of liver disease in cf. evidence acquisition a literature search of electronic databases was undertaken for relevant studies published from 1990 about liver disease in cystic fibrosis. the databases searched were: embase, pubmed and cochrane library. results cf is due to mutations in the gene on chromosome 7 that encodes an amino acidic polypeptide named cftr (cystic fibrosis transmembrane regulator). the hepatic manifestations include particular changes referring to the basic cftr defect, iatrogenic lesions or consequences of the multisystem disease. even though hepatobiliary disease is the most common non-pulmonary cause ofmortalityin cf (the third after pulmonary disease and transplant complications), only about the 33%ofcf patients presents clinically significant hepatobiliary disease. conclusions liver disease will have a growing impact on survival and quality of life of cystic fibrosis patients because a longer life expectancy and for this it is important its early recognition and a correct clinical management aimed atdelaying the onset of complications. this review could represent an opportunity to encourage researchers to better investigate genotype-phenotype correlation associated with the development of cystic fibrosis liver disease, especially for non-cftr genetic polymorphisms, and detect predisposed individuals. therapeutic trials are needed to find strategies of fibrosis prevention and to avoid its progression prior to development its related complications.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Liver Disease in Cystic Fibrosis: an Update

CONTEXT Cystic fibrosis (CF) is the most widespread autosomal recessive genetic disorder that limits life expectation amongst the Caucasian population. As the median survival has increased related to early multidisciplinary intervention, other manifestations of CF have emerged especially for the broad spectrum of hepatobiliary involvement. The present study reviews the existing literature on li...

full text

Cystic Fibrosis Liver Disease

Cystic fibrosis (CF) is the most common fatal autosomal recessive disorder in the white population with a frequency of 1 in 2500 live births. Inherited defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in abnormal regulation of salt and water movement across membranes. The overall feature of CF is that secretions are dehydrated due to water deprivation of lum...

full text

Liver disease in cystic fibrosis

Cystic fibrosis-associated liver disease (CFLD) affects ca. 30% of patients. The CFLD is now considered the third cause of death, after lung disease and transplantation complications, in CF patients. Diagnostics, clinical assessment and treatment of CFLD have become a real challenge since a striking increase of life expectancy in CF patients has recently been observed. There is no elaborated "g...

full text

Liver disease in cystic fibrosis.

The survival of patients with cystic fibrosis (CF) has progressively increased over recent decades, largely attributable to early diagnosis through newborn screening and advances in nutritional and respiratory care. As the life expectancy of patients with CF has improved, non-respiratory complications such as liver disease have become increasingly recognized. Biochemical derangements of liver e...

full text

Cystic fibrosis and liver disease

As the mean age of survival for patients with cystic fibrosis (CF) continues to improve, the diagnosis and treatment of CF liver disease (CFLD) has become a very relevant clinical issue. Cystic fibrosis liver disease is the third most frequent cause of death in CF after respiratory and transplantation complications and accounts for 2.3% of all mortality (Cystic Fibrosis Foundation, 2002). Liver...

full text

Prevalence of liver disease in cystic fibrosis.

To assess the prevalence, demography, and clinical features of liver disease among patients with cystic fibrosis the case notes of 524 patients of all ages who were attending the cystic fibrosis clinic were studied. Computer databases were used to establish the condition of the liver in a further 576 such patients. The overall prevalence of overt liver disease indicated by the presence of an en...

full text

My Resources

Save resource for easier access later


Journal title:
hepatitis monthly

جلد ۱۳، شماره ۸، صفحات ۰-۰

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023